oncolyt
virus
develop
anticanc
drug
virus
natur
nanoparticl
vast
untap
bioresourc
viral
speci
known
extraordinarili
divers
morpholog
biochem
composit
diamet
rang
nm
genom
nucleotid
singleor
doublestrand
rna
dna
genom
packag
icosahedr
helic
protein
shell
sometim
wrap
lipid
envelop
particl
protect
viral
genom
carri
cell
cell
infect
host
organ
transmit
infect
uninfect
host
deliv
suscept
target
cell
viral
genom
usurp
cellular
biosynthet
machineri
manufactur
progeni
virus
spread
adjac
cell
lead
characterist
pattern
tissu
destruct
provok
innat
adapt
immun
respons
cellular
humor
combat
infect
protect
host
futur
exposur
viru
one
pharmacolog
perspect
viral
genom
seen
new
class
tissuedestruct
drug
viral
particl
nanos
nucleic
acid
deliveri
vehicl
viru
type
adenoviru
carri
partial
gene
delet
approv
grant
base
superior
respons
rate
head
neck
cancer
patient
treat
combin
intratumor
plu
chemotherapi
compar
treat
chemotherapi
alon
durabl
respons
determin
prolong
surviv
shown
numer
addit
oncolyt
virus
current
phase
ii
clinic
test
mani
differ
countri
howev
virus
wide
approv
use
anticanc
drug
meet
stringent
criteria
safeti
efficaci
amen
pharmacolog
studi
human
subject
three
issu
subject
review
exemplifi
possibl
refer
oncolyt
measl
virus
agent
intens
studi
laboratori
safeti
oncolyt
virus
must
highli
cancer
specif
caus
minim
damag
destruct
normal
tissu
consider
also
given
possibl
oncolyt
viru
could
evolv
pathogen
propag
patient
possibl
persontoperson
transmiss
either
origin
oncolyt
viru
pathogen
deriv
possibl
step
taken
minim
risk
includ
develop
worstcas
scenario
conting
plan
specif
problem
effect
address
current
bless
divers
armamentarium
oncolyt
virus
proven
abil
propag
select
tumor
tissu
tabl
natur
oncolyt
serendipit
evolv
tissu
cultur
passag
becom
oncolyt
engin
way
enhanc
tumor
specif
target
mechan
exploit
date
classifi
four
broad
categori
transcript
translat
transduct
proapoptot
mechan
explain
relat
viral
replic
cycl
box
target
mechan
shown
figur
adenovirus
render
tumor
select
mutat
delet
gene
whose
product
essenti
viru
propag
normal
cell
tumor
cell
gene
product
prevent
apoptosi
cellcycl
arrest
infect
cell
inhibit
rb
respect
normal
cell
undergo
rapid
rbinduc
cellcycl
arrest
apoptosi
infect
oncolyt
adenoviru
lack
function
propag
viru
therebi
abort
howev
tumor
cell
rb
protein
frequent
nonfunct
adenoviru
still
propag
effici
without
fear
trigger
prematur
apoptosi
target
strategi
provid
way
exploit
defect
interferon
signal
pathway
tumor
cell
viru
infect
tend
provok
induct
type
interferon
success
virus
suppress
respons
box
virus
mutat
destroy
interferon
suppress
mechan
releas
interferon
infect
cell
signal
neighbor
cell
shut
protein
synthesi
lead
establish
antivir
state
contrast
normal
cell
tumor
cell
defect
interferon
signal
pathway
therefor
remain
suscept
viru
even
exposur
interferon
vesicular
stomat
viru
vsv
infect
provok
transcript
interferon
gene
viral
encod
matrix
protein
inhibit
mrna
transport
block
synthesi
releas
activ
interferon
vsv
therefor
render
nonpathogen
mutat
protein
longer
inhibit
interferon
releas
insert
interferon
gene
vsv
genom
nonpathogen
vsv
still
oncolyt
tumor
cell
defect
abil
produc
respond
interferon
therefor
effici
support
propag
defect
virus
second
translat
target
approach
employ
recent
good
effect
develop
oncolyt
polioviru
restrict
express
viral
gene
place
control
tissuespecif
intern
ribosom
entri
site
box
viru
replic
attach
first
step
viru
life
cycl
figur
attach
protein
surfac
virion
interact
specif
receptor
surfac
target
cell
attach
provid
trigger
entri
wherein
viral
genom
deliv
cytoplasm
target
cell
entri
occur
membran
fusion
envelop
virus
endosom
disrupt
particl
transloc
across
target
cell
membran
nonenvelop
virus
insid
infect
cell
viral
genom
transport
specif
nuclear
cytoplasm
destin
express
replic
viral
genom
copi
amplifi
viral
gene
express
structur
protein
assembl
form
new
viru
particl
interact
packag
signal
sequenc
progeni
viral
genom
form
fulli
infecti
nucleicacidcarri
progeni
viru
particl
releas
cell
viral
gene
encod
nonstructur
structur
protein
typic
express
sequenti
nonstructur
protein
express
earliest
sever
function
drive
amplif
viral
genom
induc
express
structur
late
protein
maintain
viabil
target
cell
long
enough
make
viabl
progeni
virus
first
respons
cell
upon
sens
infect
viru
scream
releas
surround
uninfect
cell
respond
interferon
signal
activ
viral
defens
mechan
suppress
translat
machineri
becom
poor
substrat
support
viru
propag
second
respons
infect
cell
activ
apoptot
program
die
releas
progeni
virus
unsurprisingli
virus
evolv
suppress
apoptosi
interferon
respons
use
mani
differ
mechan
infect
cell
therebi
bound
gag
exploit
virusproduc
factori
adenovirus
herp
virus
retrovirus
render
tumor
select
insert
tissuespecif
tumorspecif
promot
genom
regul
express
viral
gene
whose
product
essenti
viru
propag
adenovirus
achiev
place
gene
control
foreign
promot
oncolyt
herp
virus
transcript
target
effort
focus
one
key
earli
gene
retrovirus
promoterenhanc
region
long
termin
repeat
replac
viru
attach
protein
adapt
use
receptor
express
preferenti
exclus
tumor
cell
surfac
mediat
viru
entri
expos
proteas
abund
tumor
microenviron
approach
extens
valid
use
recombin
measl
virus
measl
viru
two
envelop
glycoprotein
hemagglutinin
h
attach
protein
fusion
f
protein
redirect
virion
bind
tumorassoci
receptor
ligand
growth
factor
singlechain
antibodi
insert
ctermin
extens
h
protein
mutat
ablat
interact
measl
receptor
slam
signal
lymphocyt
activ
molecul
fulli
retarget
virus
infect
kill
cell
express
cognat
receptor
display
ligand
second
transduct
target
approach
proteasesensit
linker
insert
f
protein
proteolyt
matur
f
protein
occur
exclus
site
proteas
abundantli
express
measl
virus
select
activ
tumorassoci
matrix
metalloproteinas
recent
describ
virus
evolv
mutat
select
viral
mutat
rate
gener
rel
high
higher
rna
virus
dna
virus
mani
virus
pure
viru
prepar
carri
point
mutat
somewher
genom
virotherapi
product
therefor
precis
defin
small
molecul
actual
swarm
quasispeci
close
relat
ident
consensu
product
select
pressur
treat
cancer
patient
virus
vivo
progeni
might
acquir
abil
infect
nontarget
tissu
evad
host
immun
respons
spread
patient
carer
risk
like
vari
greatli
depend
biolog
preval
oncolyt
viru
question
risk
oncolyt
viru
transmiss
treat
patient
carer
expect
higher
viru
deriv
anim
pathogen
deriv
human
vaccin
oncolyt
measl
virus
consid
extrem
safe
regard
measl
viru
origin
isol
throat
swab
measlesinfect
patient
david
edmonston
attenu
extens
tissu
cultur
passag
live
attenu
measl
vaccin
current
use
deriv
edmonston
lineag
oncolyt
strain
measl
viru
current
investig
success
global
deploy
measl
vaccin
human
immun
measl
henc
even
oncolyt
measl
viru
evolv
new
pathogen
potenti
transmiss
patient
measlesimmun
carer
would
highli
unlik
scenario
oncolyt
measl
viru
evolv
becom
pathogen
highli
unlik
revers
pathogen
close
relat
edmonstonderiv
measl
vaccin
document
billion
vaccine
vaccin
strain
shed
saliva
urin
persontoperson
vaccin
transmiss
convincingli
document
final
contrast
virus
influenza
measl
monotyp
extrem
slow
rate
evolut
explain
antimeasl
immun
acquir
vaccin
edmonston
vaccin
strain
origin
isol
still
strongli
protect
current
circul
measl
strain
year
later
efficaci
oncolyt
virus
must
capabl
penetr
host
defens
access
grow
tumor
whether
primari
metastat
must
also
capabl
propag
suffici
target
site
destroy
infect
tumor
infect
control
elimin
immun
system
cancer
patient
mani
antivir
defens
mechan
need
penetr
overcom
oncolyt
viru
effect
exampl
virus
bloodstream
neutral
antibodi
complement
bound
receptorposit
nontarget
cell
clear
phagocyt
liver
spleen
intraven
administ
virus
therefor
elimin
rapidli
circul
process
becom
faster
subsequ
exposur
increas
antivir
immun
formid
barrier
effici
accur
vascular
deliveri
virus
skeptic
express
whether
agent
ever
exploit
system
therapi
howev
uninform
neg
virotherapi
research
commun
develop
broad
rang
viabl
solut
intravascular
intraven
intraarteri
deliveri
problem
one
approach
administ
differ
viral
serotyp
success
treatment
cycl
mani
virus
eg
adenoviru
vsv
sever
natur
occur
serotyp
definit
resist
neutral
antisera
serotyp
certain
virus
also
possibl
modifi
virus
engin
evolv
longer
neutral
antibodi
rais
origin
viru
serotypeswitch
approach
applic
monotyp
virus
measl
polym
coat
virus
anoth
way
block
antibodi
recognit
primari
amino
group
surfac
adenoviru
particl
becam
modifi
polym
adenovirus
mix
poli
n
methacrylamid
phpma
bear
reactiv
onp
ester
pendent
diglycyl
sidechain
polymerco
virus
extend
circul
time
vivo
prevent
viru
bind
cellular
receptor
infect
restor
least
partial
incorpor
celltarget
ligand
polym
coat
altern
viru
modif
reduc
concentr
circul
antivir
antibodi
patient
infus
viru
might
achiev
infus
solubl
viral
antigen
pass
blood
antigenload
column
immun
antivir
antibodi
provok
antiidiotyp
antibodi
respons
sequest
antivir
antibodi
prevent
interact
infus
viral
particl
anoth
approach
reduc
concentr
antivir
antibodi
destruct
virusspecif
b
lymphocyt
antibodyproduc
plasma
cell
steroid
cyclophosphamid
antibcel
antibodi
howev
reduct
concentr
neutral
antibodi
termin
product
slow
serum
halflif
antivir
igg
longer
day
plasmapheresi
routin
use
clinic
deplet
igm
antibodi
immun
complex
approach
although
straightforward
rel
ineffect
deplet
circul
igg
altern
chang
viru
coat
suppress
antibodi
respons
recent
data
indic
could
possibl
hide
viru
seen
bound
antivir
antibodi
transit
bloodstream
gain
access
tumor
cell
popul
achiev
either
use
virusinfect
cell
carrier
transport
viru
target
cell
popul
deliv
viru
genom
target
cell
nonimmunogen
infecti
nucleic
acid
approach
potenti
circumv
phagocyt
clearanc
mechan
sequest
virus
liver
spleen
must
use
conjunct
effect
target
strategi
minim
transduct
nontarget
tissu
extravas
intraven
administ
virus
parenchyma
tumor
anoth
import
variabl
influenc
size
viral
particl
smaller
nanoparticl
extravas
better
permeabl
tumor
blood
vessel
mous
xenograft
model
perhap
primari
metastat
human
cancer
permeabl
blood
vessel
greater
tumor
peripheri
oncolyt
virus
extravas
effici
locat
vascular
permeabl
increas
local
express
vascular
permeabl
factor
vascular
endotheli
growth
factor
local
inflamm
secondari
treatment
extern
beam
radiat
chemotherapi
altern
strategi
enhanc
viral
extravas
tumor
blood
vessel
engin
attach
protein
bind
receptor
express
tumor
blood
vessel
endothelium
virus
dual
specif
neovessel
endothelium
antigen
express
tumor
cell
requir
ensur
intratumor
propag
proceed
viru
transport
across
endotheli
line
tumor
blood
vessel
depend
viru
time
infect
targetcel
death
rang
hour
day
number
progeni
releas
singl
infect
cell
burst
size
rang
thu
absenc
immun
system
oncolyt
virus
spread
tumor
wide
differ
speed
presenc
immun
system
antivir
immun
major
host
factor
serv
modul
speed
intratumor
viru
propag
import
regard
cellular
arm
immun
system
control
spread
infect
destroy
infect
cell
chanc
releas
viral
progeni
antivir
cytotox
lymphocyt
respons
suppress
immunosuppress
drug
therebi
promot
intratumor
spread
oncolyt
viru
cyclophosphamid
attract
immunosuppress
drug
use
combin
oncolyt
virotherapi
rapidli
divid
lymphocyt
exquisit
sensit
cytotox
action
proven
activ
effect
antineoplast
agent
use
extens
treatment
human
malign
cyclophosphamid
well
toler
avail
low
cost
strongli
inhibit
antivir
immun
respons
whether
primari
anamnest
b
cell
cell
administ
appropri
time
dose
follow
viru
exposur
thu
cyclophosphamid
greatli
increas
effici
viru
spread
infect
tumor
cell
adjac
uninfect
cell
help
limit
increas
antivir
antibodi
titer
success
viral
dose
pharmacokinet
describ
fate
drug
bodi
includ
absorpt
distribut
biotransform
excret
adequ
address
previou
human
virotherapi
studi
key
pharmacokinet
question
usual
left
unansw
phase
virotherapi
trial
viru
particl
go
mani
reach
target
site
ii
mani
target
cell
get
infect
locat
ident
iii
viral
genom
express
infect
cell
level
long
iv
mani
progeni
virus
releas
infect
cell
releas
go
v
fast
far
viru
spread
elimin
bodi
answer
import
question
routin
obtain
preclin
studi
direct
analysi
tissu
sampl
harvest
multipl
site
multipl
timepoint
analys
feasibl
human
trial
studi
pharmacokinet
oncolyt
virus
clinic
set
need
conveni
noninvas
monitor
strategi
use
quantifi
express
level
virusencod
protein
map
distribut
virusinfect
cell
repeat
test
undertaken
treat
patient
track
spread
viru
determin
time
cours
viral
gene
express
marker
gene
incorpor
viral
genom
facilit
type
clinic
monitor
oncolyt
measl
virus
code
solubl
extracellular
domain
human
carcinoembryon
antigen
mvcea
recent
gener
facilit
noninvas
monitor
viru
propag
human
subject
serial
measur
serum
carcinoembryon
antigen
cea
concentr
second
recombin
oncolyt
measl
viru
mvni
code
human
thyroid
sodium
iodid
symport
ni
membran
ion
channel
respons
transport
iodin
thyroid
follicular
cell
gener
mvnisinfect
cell
concentr
radioact
iodin
bloodstream
enabl
statu
infect
monitor
serial
noninvas
singlephotonemiss
comput
tomographi
spect
positronemiss
tomographi
pet
imag
use
tracer
two
recombin
measl
virus
current
test
phase
doseescal
clinic
trial
patient
ovarian
cancer
mvcea
glioma
mvcea
multipl
myeloma
mvni
transgen
encod
certain
intracellular
enzym
nonsign
cellsurfac
receptor
also
facilit
imag
thu
herp
simplex
viru
thymidin
kinas
enzym
phosphoryl
trap
radioact
fiau
tracer
virusinfect
cell
virus
express
transgen
imag
pet
spect
also
mutat
dopamin
receptor
dopamin
unabl
signal
trap
petlabel
ligand
tracer
site
viru
propag
new
monitor
strategi
expect
enhanc
qualiti
pharmacolog
inform
gain
earlystag
clinic
virotherapi
trial
provid
ration
basi
intellig
protocol
modif
hasten
inevit
clinic
success
long
incub
period
oncolyt
virus
final
emerg
potenti
use
anticanc
drug
data
current
emerg
ongo
phase
phase
ii
clinic
trial
extrem
encourag
show
tumor
regress
occur
even
system
viru
deliveri
howev
signific
challeng
remain
particular
clinic
potenc
oncolyt
virus
must
increas
becom
truli
effect
cancer
therapi
seem
like
clinic
potenti
fulli
realiz
safe
administ
patient
receiv
concurr
immunosuppress
therapi
ensur
safe
deploy
set
antibodi
deplet
transient
immunosuppress
anticip
futur
oncolyt
virus
potent
also
tumor
specif
current
test
amen
noninvas
pharmacolog
monitor
mechan
tumor
target
oncolyt
virus
transcript
target
essenti
viral
gene
place
control
tumorspecif
promot
viru
promot
natur
tumor
specif
typic
select
gene
encod
earli
viral
protein
essenti
success
complet
viru
life
cycl
applic
dna
virus
exclud
poxvirus
retrovirus
b
translat
target
viru
engin
adapt
disabl
viral
protein
antagon
cellular
interferon
ifn
respons
normal
cell
releas
interferon
upon
infect
caus
neighbor
cell
shutoff
translat
infect
cancer
cell
impair
abil
releas
respond
normal
interferon
c
proapoptot
target
viru
engin
adapt
disabl
viral
protein
prevent
apoptosi
normal
cell
die
quickli
upon
infect
progeni
virus
produc
infect
cancer
cell
impair
abil
undergo
apoptosi
henc
viru
gener
progeni
spread
cancer
cell
transduct
target
viru
gain
entri
target
cell
receptor
express
abundantli
tumor
cell
normal
cell
natur
receptor
sever
virus
fall
categori
altern
attach
specif
viru
reprogram
toward
tumor
antigen
display
singlechain
antibodi
polypeptidebind
ligand
viral
surfac
trend
pharmacol
sci
author
manuscript
avail
pmc
june
abbrevi
daf
decay
acceler
factor
egfr
epiderm
growth
factor
receptor
fr
folat
receptor
ire
human
rhinoviru
type
htert
human
telomeras
promot
icam
intracellular
cell
adhes
icp
infect
cell
protein
nonstructur
psa
prostatespecif
antigen
viral
serin
proteas
inhibitor
tk
thymidin
kinas
